

COMMISSIONED RESEARCH

NEWS FLASH 05 February 2025 Sweden

Upcoming events

Q3 Report: 05 Feb 2025

Q4 Report: 09 May 2025

Capital Goods

Research analysts: Markus Almerud

Share price: SEK325.0

Fair value range: SEK306.0-376.0

Bergman & Beving

20 quarters in a row with EBITA growth – Q3 first take

Organic growth down 5% Y/Y in Q3...

The economic climate remains difficult in the construction and manufacturing sectors in the Nordics. Bergman & Beving's (B&B) organic growth in Q3 was -5% Y/Y, leading to sales coming in 2% below Modular Finance consensus and 3% below our forecast. The number of employees in the construction and manufacturing sectors, which is the key driver of B&B's sales, decreased during the autumn. The company comments that it does not see the pressure waning in the near future.

...but continuous margin expansion

Although the EBITA margin was 90bps lower sequentially, the margin expansion continued Y/Y, and B&B has now grown EBITA for 20 quarters in a row. The EBITA margin grew 30bps to 9.6% in Q3. Consensus was 9.8% and EBITA was 4% below consensus expectations. B&B continues to optimise operations and cut costs to meet the state of the market. We would expect low single-digit cuts to consensus estimates.

Four acquisitions added in the quarter

M&A continues to be a key driver for growth, and B&B added four companies in the quarter, corresponding to annualised sales of SEK310m. The contribution from acquisitions to sales in Q3 was 11%-points, therefore the company grew the top line despite negative organic growth. B&B looks for companies with EBITA margins over 15%, meaning that the add-ons are margin accretive. We expect the M&A trend to continue.

Conference call at 09.00 CET

We will look for more colour on the state of demand and an update on the M&A environment.

Key facts	
No. shares (m)	26.7
Market cap. (USDm)	791
Market cap. (SEKm)	8,681
Net IB Debt. (SEKm)	2,188
Adjustments (SEKm)	0
EV (2024e) (SEKm)	10,869
Free float	82.6%
Avg. daily vol. ('000)	19
Risk	High Risk
Fiscal year end	March
Share price as of (CET)	04 Feb 2025 17:29

Key figures (SEK)	2023	2024e	2025e	2026e
Sales (m)	4,723	5,051	5,428	5,631
EBITA (m)	438	520	588	629
EBITA adj. (m)	438	520	588	629
EPS	7.13	9.01	10.9	12.3
EPS adj.	9.59	12.0	13.9	15.2
DPS	3.80	4.50	5.00	5.00
Sales growth Y/Y	-1%	7%	7%	4%
EPS adj. growth Y/Y	2%	25%	16%	10%
EBITA adj. margin	9.3%	10.3%	10.8%	11.2%
EV/Sales	2.3	2.2	2.0	1.8
EV/EBITA adj.	17.5	20.9	18.2	16.5
EV/EBITA	17.5	20.9	18.2	16.5
EV/EBIT	20.6	24.7	21.0	19.0
P/E adj.	33.9	27.1	23.4	21.3
P/BV	4.1	3.9	3.6	3.3
Dividend yield	1.2%	1.4%	1.5%	1.5%
FCF yield	7.0%	4.9%	5.7%	6.8%
ROCE	8.4%	9.6%	10.8%	11.7%
ROE adj.	12.0%	14.8%	16.0%	16.2%
Net IB debt/EBITDA	3.1	3.0	2.4	1.9



2.6 -1.7

Source: Carnegie Research, FactSet, Millistream & company data

This report has been commissioned and sponsored by Bergman & Beving. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas. For more information, see disclosures and disclaimers at the end of this report

Carnegie® Access



B&B deviation table	2023/24	2024/25				Consensus		Carnegie		[
SEKm	Q3	Q4	QI	Q2	Q3a	Q3e	Dev	Q3e	Dev	23/24	24/25e	25/26e	26/27e
Sales	1,187	1,214	1,253	1,144	1,264	1,291	-2%	1,306	-3%	4,723	5,051	5,428	5,631
Growth	-4%	-2%	2%	5%	4%	9%	-4.6рр	10%	-5.9рр	-1%	7%	7%	4%
Organic	-12%	-12%	-7%	-3%	-5%	-1%	-3.7рр	0%	-5рр	-10%	-2%	4%	4%
Acquisitions	8%	10%	9%	9%	11%	10%	0.6рр	10%	0.6рр	9%	9%	4%	0%
Currency	0%	0%	0%	-1%	0%	0%	0.4рр	0%	0.4рр	1%	0%	0%	0%
Adj EBITA	110	116	119	120	121	126	-4%	138	-13%	438	520	588	629
Adj EBITA margin	9.3%	9.6%	9.5%	10.5%	9.6%	9.8%	-0.2pp	10.6%	-Ipp	9.3%	10.3%	10.8%	11.2%
PPA	-16	-19	-19	-20	-23	-20	15%	-20	15%	-66	-80	-80	-80
EO	0	0	0	0	0	0	n.m	0	n.m	0	0	0	0
EBIT	94	97	100	100	98	106	-8%	118	-17%	372	440	508	549
EBIT margin	7.9%	8.0%	8.0%	8.7%	7.8%	8.2%	-0.5рр	9.1%	-1.3рр	7.9%	8.7%	9.4%	9.7%
Net financials	-24	-32	-26	-27	-28	-27	3%	-26	8%	-111	-105	-102	-93
Pre-tax Profit	70	65	74	73	70	79	-11%	92	-24%	261	335	406	456
Tax	-15	-16	-16	-18	-16	-20	-19%	-21	-25%	-60	-77	-93	-105
Tax rate	21%	25%	22%	25%	22.9%	25%	-2.2рр	23%	-0.1рр	23%	23%	23%	23%
Net profit	52	46	52	52	54	59	-9%	68	-21%	191	243	294	330
EPS (SEK)	1.94	1.72	1.93	1.93	2.00	2.14	-7%	2.53	-21%	7.1	9.0	10.9	12.3
EPS Adj (SEK)	2.54	2.43	2.63	2.67	1.95	2.14	- 9 %	3.27	-40%	9.6	12.0	13.9	15.2

Source: Carnegie Research, Modular Finance, Company data

2 05 February 2025



Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finansivalvonta). In Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet). This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule ISa-6 of the Securities Exchange Act of I934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule ISa-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc. takes responsibility for the commissioned research report. Any US person who wishes to effect ansactions based on this commissioned research report should contact Carnegie Inc. Investors in the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission. This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie UK is authorised and regulated by the F

Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the IIS

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading. Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

Parts of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2025 Carnegie



Commissioned Research sponsored by Bergman & Beving

05 February 2025

Carnegie Investment Bank AB

Regeringsgatan 56 SE-103 38 Stockholm

Tel +46 8 5886 88 00 Fax +46 8 5886 88 95 www.carnegie.se

A member of the Stockholm Stock Exchange

Carnegie AS

Fjordalleen 16, 5th Floor PO Box 684, Sentrum NO-0106 Oslo Tel +47 22 00 93 00 Fax +47 22 00 94 00 www.carnegie.no A member of the Oslo Stock Exchange Carnegie Investment Bank, Denmark Branch

Overgaden neden Vandet 9B PO Box 1935 DK-1414 Copenhagen K

Tel +45 32 88 02 00 Fax +45 32 96 10 22 www.carnegie.dk

A member of the Copenhagen Stock Exchange

Carnegie, Inc.

20 West 55th St. ,
New York N.Y. 10019
Tel +1 212 262 5800 Fax +1 212 265 3946
www.carnegiegroup.com
Member FINRA / SIPC

Carnegie Investment Bank AB, Finland Branch

Eteläesplanadi 2 PO Box 36 FI-00131 Helsinki

Tel +358 9 618 71 230 Fax +358 9 618 71 720 www.carnegie.fi

A member of the Helsinki Stock Exchange

Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square London EC2A IDS

Tel +44 20 7216 4000 Fax +44 20 7417 9426 www.carnegie.co.uk

Regulated by the FCA in the conduct of Designated Investment Business in the $\ensuremath{\mathsf{UK}}$